CA-PROSIMO
12.6.2024 16:01:30 CEST | Business Wire | Press release
Prosimo, a leader in multi cloud networking software [MCNS], today announced an integration with Palo Alto Networks for a powerful new approach to security that protects applications and workloads in multi cloud environments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240612713674/en/
Hop by Hop Traceability Including the Packets Being Actioned Within a Firewall (Graphic: Business Wire)
With Prosimo’s Full Stack Cloud Transit platform, customers can seamlessly integrate with Palo Alto Networks VM-Series Virtual Next-Generation Firewall (NGFW), allowing enterprises to deploy security as close as possible to the workloads they protect. This architecture greatly reduces the time and effort required to secure application access across multi cloud environments for users and workloads.
“Together with Palo Alto Networks VM-Series virtual firewalls, we’re providing organizations with a Zero Trust framework so they can be confident their application workloads are secure while ensuring fast and reliable connectivity to and across cloud providers,” said Prosimo Vice President of Product Mani Ganesan. “This integration allows enterprises to improve observability, increase operational efficiency, and safely gives them more control of their cloud environment.”
Join the Office Hours to explore the use case and see a live demo here.
Most integrations today focus on orchestrating firewalls and inserting them in the path of cloud network traffic, where they rely on IP addresses/port numbers to redirect traffic. Prosimo instead provides service insertion policies that allow users to define sophisticated rules that determine which traffic will be routed for advanced inspection to the firewall.
Prosimo simplifies deployment for two flexible architectures for Palo Alto Networks VM-Series virtual firewalls:
- Centralized: VM-Series virtual firewall is deployed into a centralized VPC for east-west (VPC-to-VPC) or north-south (Internet egress and ingress, cloud to on-premises) traffic. This is the most common Prosimo model and provides security control and ongoing manageability.
- Distributed: VM-Series virtual firewalls are deployed in each virtual private cloud. This method is typically used in cases where VPCs need to be isolated and require local ingress or egress.
“Speed is critical in the cloud, so the speed of operations in configuring software firewalls, like the VM-Series virtual firewall, needs to match the speed of cloud deployments,” said Vitaliy Sivetskiy, senior product manager of Palo Alto Networks. “Integrating Prosimo’s Full Stack Cloud Transit and Palo Alto Networks VM-Series virtual firewall makes network security teams' lives easier. Our single intuitive operating model for connectivity and virtual firewall insertion means customers have more time to focus on application business innovation versus managing network and security infrastructure. This enables organizations to help protect all clouds, the right way, with agility.”
Providing Multi-Layer Security to Navigate Cloud Firewall Complexity
While a well-constructed multi cloud networking architecture can enhance security, scaling of firewalls can be complex. Common challenges include ensuring the virtual firewall can handle the required elasticity associated with growing cloud resources, managing complex network configurations for auto scaling, and implementing ongoing route updates to direct traffic through the next-generation firewall while maintaining segmentation and isolation.
Integrating Prosimo with Palo Alto Networks VM-Series virtual firewalls ensures enhanced security and scalability across the network and application layer. Palo Alto Networks Next-Generation Firewalls offer comprehensive Layer 7 inspection, while Prosimo stands out as a leading provider in the MCNS market capable of delivering network segmentation spanning Layer 3 to Layer 7.
With native integration, customers can provision new virtual firewalls in a few clicks. From a single dashboard, users can manage the lifecycle of those firewalls, quickly scaling up or down while segmenting the necessary subnets and corresponding cloud-native elements.
Customers can see immediate benefits from the integration through:
- Migrating to Palo Alto Networks software next-generation firewalls faster, eliminating blind spots for both network and security teams.
- Right-sizing software firewalls to optimize cloud costs.
- Using the existing firewall investment to segment east-west and north-south data movement within clouds.
Go to prosimo.io to learn how Prosimo and Palo Alto Networks enable enterprises to build, modernize, and future-proof cloud infrastructure.
About Prosimo
Prosimo delivers a simplified multicloud infrastructure for distributed enterprise cloud journeys. Companies innovate faster and remain in control with the Prosimo integrated stack. This stack combines cloud networking, performance, security, observability, and cost management—all powered by data insights and machine learning models with autonomous cloud networking to reduce complexity and risk. Cloud-forward enterprises, including F100, have successfully adopted Prosimo to roll out revenue-generating applications, improve operational efficiency, and accelerate positive business outcomes. Prosimo is venture-backed by marquee investors such as General Catalyst, WRVI Capital, and Blackrock. For more information, visit https://www.prosimo.io.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240612713674/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
